Chemotherapy Foundation Symposium

Chemotherapy Foundation Symposium XXVIII

Tuesday, November 9

Pediatric Oncology Chair: Gustavo Del Toro, MD
1:30		Complementary/Alternative Therapies in Pediatric Oncology Elena Ladas, MD
1:45		"TARGETED" THERAPEUTICS AGAINST SARCOMAS OTHER THAN GIST Robert Maki, MD
2:00		Ewing’s Sarcoma Dr. Linda Granowetter, MD
2:15		NEUROBLASTOMA Shakeel Modak, MD
2:30		Thyroid Cancer in Children Kaare Weber, MD
2:45		GERM CELL TUMORS Lindsay Frazier, MD
3:00		Coffee Time
3:15		Ethical Aspects of Pediatric Oncology Edwin Forman, MD
3:30		Response Based Treatment of Hodgkin’s Lymphoma: Improving Efficacy and Reducing Long Term Toxicity Cindy Schwartz, MD
3:45		Acute Promyelocytic Leukemia John Gregory, MD
4:00		EpratUzumab in Childhood Acute Lymphoblastic Leukemia Elizabeth Raetz, MD
4:15		Treosulfan in Pre-Transplant Conditioning of Pediatric Patients Eneida Nemecek, MD
4:30		Graft-vs-Host Disease John Levine, MD
4:45		The Infant ALL Gene Expression Profiles Ronald Stam MD
5:00		Anti-Emetics in Pediatric Oncology Olga Militano, MD
5:15		OncoEd
7 -9 pm		Dinner and Presentation

Wednesday, November 10

7:00		Breakfast with the Professors
		Sequencing and RETreatment: Case Studies in Multiple Myeloma Asher Chanon-Khan, MD, Sergio Giralt, MD
8:00		Welcome Steven Burakoff, MD, Janice L. Gabrilove, MD, Edward P. Ambinder, MD
Morning Session
Hematology Moderators: Janet Cuttner, MD, Janice L. Gabrilove, MD, Kanti Rai, MD
		Lymphoid Malignancies
8:10		EMERGING ROLE OF PRALATREXATE in B- and T- Cell Lymphomas Owen O’Connor, MD
8:20		New Agents in Follicular NHLs John Leonard, MD
8:30		Bendamustine and other ACTIVE agents in NHL Bruce Cheson, MD
		Multiple Myeloma
8:45		New Drugs Advancing treatment of Multiple Myeloma Sundar Jagannath, MD
		CLL
9:00		Recently Approved Agents in Therapy of CLL Kanti Rai, MD
9:15		CAL-101, AN ORAL ISOFORM-SELECTIVE INHIBITOR IN RELAPSED OR REFRACTORY B-CELL MALIGNANCIES Ian Flinn, MD
9:30		NEWER AGENTS IN THE TREATMENT OF WALDENSTROM'S MACTOGLOBULINEMIA Steven Treon, MD
		Myeloid Malignancies
9:50		TREATMENT OF EARLY MYELOFIBROSIS WITH INTERFERON Richard Silver, MD
10:05		Coffee Time
10:35		New Therapeutic Approaches in P Vera and other MPDs Ronald Hoffman, MD
		CML
10:50		New strategies in the treatment of CML Elias Jabbour. MD
11:05		DEFOROLIMUS (MK-8669) IN CML Frank Giles, MD
		MDS
11:15		New Directions Lewis Silverman, MD
		AML
11:25		Voreloxin in AML Robert Stuart, MD
11:35		MANAGEMENT OF AML IN THE ELDERLY Janice Gabrilove, MD
11:50		Discussion
12:00		OncEd
12:05		LUNCH AND PRESENTATIONS
		Refractory AML Treatment Options Janice Gabrilove, MD
		Role of Transplants Meir Wetzler, MD
Afternoon Session

1:15		KEYNOTE SPEAKER CANCER CELL SEEDING: A HYPOTHESIS WITH THERAPEUTIC IMPLICATIONS Larry Norton, MD
GI CANCERS Moderators: Jordan Berlin, MD, Howard S. Hochster, MD
1:45		GASTRIC CANCER: TesetaxeL, A novel oral taxane in development Jaffer Ajani, MD
2:00		Beyond RAZ: ARE THERE OTHER MARKERS FOR EFFICACY IN COLON CANCER? Heinz Lenz. MD
2:15		ANGIOGENESIS AND COLORECTAL CANCER James Abbruzzese, MD
2:30		SONIC HEDGEHOG IN COLORECTAL CANCER Jordan Berlin, MD
2:40		PERIFOSINE: DO WE FINALLY HAVE A NEW AGENT TO TREAT REFRACTORY COLORECTAL CANCER? Johanna Bendell, MD
2:50		HOW DO WE INTERPRET THE DATA IN ANAL CANCER? Cathy Eng, MD
3:00		Coffee Time
3:30		ADVANCES IN THE SYSTEMIC TREATMENT OF BILIARY TRACT CANCERS Laura Williams Goff, MD
3:40		ALN-VSP02 IN LIVER CANCER Howard Burris, MD
3:50		ISLET CELL TUMORS: NEW STRATEGIES IN THE ERA OF TARGETED AGENTS Matthew Kulke, MD
4:05		DIET AND LIFESTYLE AFTER COLORECTAL CANCER DIAGNOSIS: DOES IT MATTER? Jeffrey Meyerhardt, MD, MPH
4:20		Endoscopic management of patients at high risk for developing CRC Steven Itzkowitz, MD
4:35		Discussion
4:45		OncEd
7 - 9 pm		DINNER PRESENTATION CURRENT STATUS OF TREATMENT IN NHL John Leonard, MD

THURSDAY, NOVEMBER 11

7:00		Breakfast with the Professors
		EXPANDING ROLE OF BIOMARKERS Robert Bast, MD . Treating Ovarian Cancer with PARP inhibitors Alice Chen, MD
Morning Session
Gynecological Cancers Moderators: Franco Muggia, MD, Carmel Cohen, MD, Tamar Safra, MD
8:00		Antiangiogenesis: effects on drug pharmacology Franco Muggia, MD
8:15		THE ROLE OF CA125 IN THE FOLLOW UP OF OVARIAN CANCER Gordon Rustin, MD
8:30		UPDATES ON BIOMARKERS FOR MANAGEMENT OF EPITHELIAL OVARIAN CANCER Robert Bast, MD
8:45		NATIONAL AND INTERNATIONAL TRIALS William McGuire, MD
9:00		UPDATE ON SGO AND CLINICAL TRIALS Thomas Herzog, MD
9:15		PERSPECTIVES ON THE GOG STUDIES Michael Bookman, MD
9:30		New Strategies in the clinical treatment of endometrial cancer Don Dizon, MD
9:45		'Brcaness’ Explaining response to Chemotherapy and to Parp Inhibitors Don Dizon, MD
10:00		Coffee Time
10:30		MOLECULAR TARGETS Nicoletta Colombo, MD
10:45		Discussion
10:55		OncEd
THYROID
11:00		Thyroid cancer: new treatment options Dimitrios Colevas, MD
HEAD AND NECK
11:15		Panitumumab IN HEAD AND NECK CANCER To Be Announced
ALL
11:30		NEW TREATMENT PARADIGMS FOR ADOLESCENTS AND YOUNG ADULTS WITH ALL Wendy Stock, MD
11:45		Discussion
11:55		OncEd
		LUNCH AND PRESENTATIONS
12 Noon		INCORPORATING GENOMICS INTO THE CLINICAL PRACTICE OF CANCER CARE Harold Burstein, MD, Norman Wolmark, MD
1:20		EZRA M. GREENSPAN MEMORIAL LECTURE Integrating Targeted Therapeutics with Standard Therapy - Novel Agents and Trial Designs Joseph Sparano, MD
Afternoon Session
BREAST CANCER Moderators: Seymour Cohen, MD, Larry Norton, MD, George Raptis, MD
1:40		An ovarian dilemma: Adjuvant therapy in early breast cancer Norman Wolmark, MD
1:55		NEW AGENTS FOR RESISTANT METASTATIC BREAST CANCER Linda T. Vahdat, MD
2:10		NK012: A novel camptothecin formulation with activity in triple negative breast cancer Howard Burris, MD
2:20		MECHANISMS OF RESISTANCE TO HER2 KINASE INHIBITORS Neil Spector, MD
2:35		P13K INHIBITORS: INITIAL RESULTS AND FUTURE DIRECTIONS Jose Baselga, MD
2:50		Coffee Time
3:20		PREOPERATIVE PACLITAXEL WITH RADIATION THERAPY IN LOCALLY ADVANCED BC: PATHOLOGICAL RESPONSE PREDICTS FOR SURVIVAL Sylvia Adams. MD
3:35		NEXT GENERATION ANTI-HER2 THERAPIES Ian Krop, MD, PhD
3:50		ANGIOGENESIS INHIBITORS: WHERE ARE WE NOW IN BREAST CANCER? Harold Burstein, MD
4:05		PARP Inhibitors: application in breast cancer Daniel Silver, MD
4:20		SCH-727965 a novel CDK inhibitor: updated results in BREAST CANCER Monica Mita, MD
4:30		MANAGEMENT OF Triple negative breast cancers Hope Rugo, MD
4:40		Targeted Epigenetic Therapy of Breast Cancer Samuel Waxman, MD
4:50		OncEd
7 - 9pm		Dinner and Presentation To Be Announced


Friday, November 12

7:00		Breakfast with the Professors
		PERSONALIZED MEDICINE FOR GU CANCERS: STATE OF THE ART Chair: William Oh, MD
		GENOMICS AND PROSTATE CANCER IN 2010 Philip Febbo, MD
		NEW TARGETS AND NEW DRUGS IN PC Phil Kantoff, MD

URO-ONCOLOGY Moderators: Anna C Ferrari, MD, William K. Oh, MD
		Prostate Cancer
8:00		RISING PSA IN NON-CASTRATE PATIENTS: NEW THERAPEUTIC APPROACHES Mark Stein, MD
8:15		CABAZITAXEL, SECOND LINE IN CASTRATION RESISTANT PC Oliver Sartor, MD
8:30		VACCINE EFFICACY IN CASTRATION RESISTANT PC James L. Gulley, MD
8:45		TAK-700, A NEW HORMONAL AGENT IN CASTRATION RESISTANT PC Robert Dreicer, MD
9:00		bicalutamide IN CASTRATION RESISTANT PC Anna Ferrari, MD
9:15		"BRCANESS" AS A MARKER OF PLATINUM SENSITIVITY IN PC William Oh, MD
		Bladder Cancer
9:30		NEW THERAPEUTIC APPROACHES TO BLADDER CANCER Matt Galsky, MD
		Renal Cell Cancer
9:45		SEQUENCING TKIs AND mTOR INHIBITORS IN RENAL CELL CARCINOMA Toni Choueiri, MD
10:00		Discussion
10:10		OncED
10:20		Coffee Time

LUNG CANCER Moderators: Chandra Belani, MD, Roman Perez-Soler, MD
10:30		NOVEL AGENTS IN LUNG CANCER IGF-IR INHIBITORS Corey Langer, MD
10:45		PF-1066 and EML4-ALK FUSION GENE Chandra Belani, MD
11:00		PACLITAXEL: NEW REGIMEN Mark Socinski, MD
11:15		THE BATTLE TRIAL: A STEP TOWARDS PERSONALIZED THERAPY FOR LUNG CANCER Edward Kim, MD
11:30		RECENT ADVANCES AND CHANGES IN TREATMENT PARADIGM IN ADVANCED NSCLC Chandra Beleni, MD
11:45		ADVANCES IN THORACIC SURGICAL TECHNIQUES AND LUNG CANCER IMAGING Nasser Altorki, MD
11:55		OncED
12:05		Lunch and Presentations
		MOLECULAR CHARACTERIZATION OF NSCLC Chair: Chandra Belani, MD
		REVERSIBLE AND IRREVERSIBLE EGFR INHIBITORS: SENSITIVITY AND RESISTANCE S. Ramalingam, MD & Roman Perez-Soler, MD

JUDAH FOLKMAN MEMORIAL LECTURE
1:30		TRANSLATING TRANSLATIONAL CONTROL INTO ANTI-ANGIOGENIC THERAP Robert Schneider, PhD

DIVERSE THERAPEUTICS Moderators: Edward Ambinder, MD, Sylvia Adams, MD

1:50		UPDATED DATA ON DENOSUMAB IN BREAST, PROSTATE AND OTHER SOLID TUMORS Allan Lipton, MD
2:05		MANAGEMENT OF ELDERLY PATIENTS WITH CANCER Supriya Gupta Mohile, MD

MELANOMA
2:20		BRAF-VALIDATED TARGET IN METASTATIC MELANOMA Igor Puzanov, MD
2:30		MEK INHIBITORS Jeff Infante, MD
2:40		PREDICTING SITE-SPECIFIC METASTASES IN PATIENTS WITH PRIMARY MELANOMA Iman Osman, MD
2:50		TARGETED T CELL ANTIBODIES IN METASTATIC MELANOMA --BREAKING THE OVERALL SURVIVAL BARRIER: FROM DARKNESS TO LIGHT Steven O’Day, MD
3:00		Discussion
3:10		OncED
3:15		Coffee Time

OTHER
3:30		ENDOCRINE PANCREATIC TUMORS RAD-2,3 James Yao, MD
3:40		MULTITASKING EXTENSIVE SURGERY FOR ADVANCED NEUROENDOCRINE TUMORS: IS IT SAFE AND EFFECTIVE? Michail Shafir, MD
3:50		MEDULLOBLASTOMA AND BASAL CARCINOMA OF THE SKIN LDE225: AN ACTIVE, ORALLY BIOAVAILABLE INHIBITOR OF THE HEDGEHOG PATHWAY Alain Mita, MD
4:00		MOLECULAR DIAGNOSIS: EVOLVING UNDERSTANDING OF CANCER OF UNKNOWN PRIMARY F. Anthony Greco, MD
4:10		INTERNATIONAL COLLABORATION IN CLINICAL TRIALS Bob Comis. MD
4:20		Discussion
4:30		OncEd
Saturday, November 13

		TBA

Conference Management Director: Jaclyn Silverman email: Jaclyn.silverman@mssm.edu | Phone 212 866 2813


	November 9-13, 2010 Marriott Marquis, New York City